Company Research Report: AroCell AB

Company Overview

Name: AroCell AB

Mission: Saving lives with diagnostics by providing knowledge to decision.

Founded Year and Founders: No information is available.

Key People: Anders Hultman (CEO).

Headquarters: Karlsbodavägen 39, 168 67 Bromma, Stockholm, Sweden.

Number of Employees: No information is available.

Revenue: No information is available.

Core Focus: AroCell is known for its broad product portfolio of in vitro diagnostic (IVD) tests aiding in the monitoring of oncological and bacterial diseases. The company is a valuable diagnostic partner for healthcare professionals.

Products

UBC® Rapid | Bladder Cancer Detection

Description: A point-of-care test designed for the primary diagnosis and monitoring of bladder cancer.

Key Features: Provides rapid results, aids in reducing the need for invasive cystoscopies.

TUBEX® TF | Rapid Typhoid Detection

Description: A rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever.

Key Features: Offers rapid results (within 10 minutes), highly sensitive and specific, easy access.

TK 210 ELISA | Cell Proliferation Biomarker

Description: A cell proliferation biomarker used to evaluate therapy response in cancer patients.

Key Features: Applies to various cancer types including solid tumors, valuable for translational biomarker purposes.

Partnerships and Licensing

Tumor markers licensed: AroCell engages in constant partnerships to develop new products and expand its diagnostic portfolio.

Recent Developments

New Products and Features

No new products or features are explicitly mentioned in the recent data.

Collaborations and Events

Redeye’s Technology & Life Science Day (Dec 3, 2024): CEO Anders Hultman presented company developments and future prospects.

Medica Trade Fair (Nov 2024): AroCell participated as an exhibitor to showcase modern healthcare diagnostics.

Airlangga University Collaboration (Jun 2024): Visit from Airlangga University and Dr. Soetomo General Hospital to discuss potential collaboration, reflecting strong engagement in key markets in Indonesia.

Participation in Major Conferences (April 2024): Engaged in events including AACR Annual Meeting 2024 in San Diego, and EAU Congress 2024 in Paris, aiming at advancing cancer research and diagnostics.

Market Approach and Strategy

AroCell continues to focus on increasing sales volumes in existing markets and obtaining market approvals in new prioritized areas with significant growth potential, while aiming to become the gold standard in oncologic diagnostics.

Strategic Focus

Concentrated efforts on expanding the next generation of IVD tests and partnering with strategic players to enhance their portfolio.

This report offers an extensive insight into AroCell AB's current market standing, product offerings, strategic partnerships, and recent activities. This information underscores the company's commitment to innovation in the diagnostics field, particularly in the battle against oncological and bacterial diseases.